TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06049680: A Single-arm Open-label Safety Study of SMOFlipid to Evaluate the Risk of Developing Essential Fatty Acid Deficiency (EFAD) and/or Parenteral Nutrition-associated Cholestasis (PNAC) in Pediatric Patients 1 Month to 17 Ye

Sponsor: Fresenius Kabi · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 100 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$5,312,000

Rescue Site Savings

+$3,505,920

Unlock Full NCT06049680 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06049680 Rescue Dossier →